Page last updated: 2024-11-07

angiotensin ii, des-asp(1)-des-arg(2)-ile(5)-

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

angiotensin II, des-Asp(1)-des-Arg(2)-Ile(5)-: 3-8 hexapeptide fragment of angiotensin II; smallest potent angiotensin II antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID123814
CHEMBL ID261120
CHEBI ID80127
SCHEMBL ID4322236
MeSH IDM0060230

Synonyms (54)

Synonym
smr000058913
MLS000069773 ,
val-tyr-ile-his-pro-phe
angiotensin ii, 1-des-asn-2-arg
angiotensin iv
12676-15-2
CHEMBL261120 ,
23025-68-5
(2s)-2-[[(2s)-1-[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid
SCHEMBL4322236
angiotensin iv, 3-l-isoleucine-
huamn angiotensin (3-8)
alanine, 3-phenyl-n-(1-(n-(n-(n-l-valyl-l-tyrosyl)-l-isoleucyl)-l-histidyl)-l-prolyl)-
angiotensin ii (3-8)
human angiotensin iv
1-de-l-aspartic -2-de-l-arginine-5-l-isoleucineangiotensin ii
angiotensin ii, des-aspartyl(1)-des-arginyl(2)-isoleucine(5)-
angiotensin ii, des-asp(1)-des-arg(2)-ile(5)-
nle-angiv
ile3-angiotensin iv
human angiotensin hexapeptide (3-8)
(des(asp1,arg2)-ile5)angiotensin ii
(isoleucine5)-angiotensin ii hexapeptide
5-isoleucine-angiotensin ii 3-8-hexapeptide
alanine, 3-phenyl-n-(1-(n-(n-(n-valyltyrosyl)isoleucyl)histidyl)prolyl)-
(ile5)-angiotensin ii (3-8)
(a)ii(3-8)
(3-8)-5-isoleucine-angiotensin ii
1-de-asp-2-de-arg-5-ile-angiotensin ii
angiotensin ii, 1-de-l-aspartic acid-2-de-l-arginine-5-l-isoleucine-
cas_12676-15-2
cid_123814
bdbm85550
ang iv
HMS2232C15
angiotensin iv trifluoroacetate salt
gtpl5368
at ii (3-8)
angiotensin ii (3-8), human
valyl-l-tyrosyl-l-isoleucyl-l-histidyl-l-prolyl-l-phenylalanin
(2s)-2-{[(2s)-1-[(2s)-2-[(2s,3s)-2-[(2s)-2-[(2s)-2-amino-3-methylbutanamido]-3-(4-hydroxyphenyl)propanamido]-3-methylpentanamido]-3-(1h-imidazol-5-yl)propanoyl]pyrrolidin-2-yl]formamido}-3-phenylpropanoic acid
angiotensin iv trifluoroacetate salt, >=95% (hplc), powder
mfcd00167496
angiotensin i/ii (3-8) (h-val-tyr-ile-his-pro-phe-oh)
NCGC00167590-02
3-l-isoleucine-angiotensin iv
CHEBI:80127
(s)-2-((s)-1-((s)-2-((2s,3s)-2-((s)-2-((s)-2-amino-3-methylbutanamido)-3-(4-hydroxyphenyl)propanamido)-3-methylpentanamido)-3-(1h-imidazol-4-yl)propanoyl)pyrrolidine-2-carboxamido)-3-phenylpropanoic acid
Q66087802
HY-P1515
CS-0044614
angiotensin ii (3-8), human?
DTXSID701347717
AKOS040758825

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Chronic angiotensin IV treatment in ApoE-/- mice evoked a marked vasoprotective effect that appeared to be mediated by improved NO bioavailability as a result of AT4 and/or AT2 receptor stimulation."( Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice.
Drummond, GR; Gaspari, TA; Vinh, A; Widdop, RE, 2008
)
0.35
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The peptides produced dose-related increases in perfusion pressure, and dose-response curves to all six peptides were parallel."( Analysis of responses to angiotensin peptides in the hindquarters vascular bed of the cat.
Garrison, EA; Kadowitz, PJ; Osei, SY; Santiago, JA, 1995
)
0.29
" Meclofenamate and N omega-nitro-L-arginine methyl ester shifted the dose-response curve for ANG IV to the left in a manner similar to that observed with ANG II and ANG III."( Analysis of responses to ANG IV: effects of PD-123319 and DuP-753 in the pulmonary circulation of the rat.
Feng, CJ; Kadowitz, PJ; Kaye, AD; Nossaman, BD, 1995
)
0.29
" Dose-response curves for both peptides were parallel, and the time-to-peak increase in lobar arterial pressure in response to angiotensin IV and angiotensin II was similar whereas the duration of the response to angiotensin IV was significantly shorter."( Analysis of responses to angiotensin IV in the pulmonary vascular bed of the cat.
Cheng, DY; Dent, EL; DeWitt, BJ; Kadowitz, PJ; Nossaman, BD, 1994
)
0.29
", the dose-response curve for angiotensin II was shifted to the right in a parallel manner, whereas the administration of higher doses resulted in nonparallel rightward shifts of the angiotensin II dose-response curves."( Analysis of the effects of candesartan in the mesenteric vascular bed of the cat.
Champion, HC; Kadowitz, PJ, 1997
)
0.3
", candesartan shifted the dose-response curve to angiotensin II to the right in a nonparallel manner, suggesting a noncompetitive blockade."( Inhibitory effects of candesartan on responses to angiotensin peptides in the hindquarters vascular bed of the cat.
Champion, HC; Kadowitz, PJ; Lambert, DG, 1998
)
0.3
" The slope of the dose-response curve for L-163,491 was flat, while the apparent affinity of the compound for angiotensin AT(1) receptors was slightly greater than angiotensin IV."( L-163,491 is a partial angiotensin AT(1) receptor agonist in the hindquarters vascular bed of the cat.
Champion, HC; De Witt, BJ; Garrison, EA; Kadowitz, PJ, 2000
)
0.31
" The effects of ANG III exhibited complex dose-response relations."( Effects of different angiotensins during acute, double blockade of the renin system in conscious dogs.
Bie, P; Plovsing, RR; Sandgaard, NC; Wamberg, C, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Renin-angiotensin pathway (COVID-19 Disease Map)116
Renin-angiotensin system110

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency15.84890.044717.8581100.0000AID485294
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency50.11870.631035.7641100.0000AID504339
Chain A, CruzipainTrypanosoma cruziPotency14.98710.002014.677939.8107AID1476; AID1478
GLS proteinHomo sapiens (human)Potency12.58930.35487.935539.8107AID624170
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency17.78280.707912.194339.8107AID720542
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aminopeptidase NHomo sapiens (human)Ki0.63970.00081.956910.0000AID329318; AID344307; AID468340; AID601498
Interleukin-1 receptor antagonist proteinHomo sapiens (human)IC50 (µMol)0.25120.25120.25120.2512AID1664906
Type-1 angiotensin II receptorHomo sapiens (human)Ki0.40740.00020.18374.7000AID329321; AID468344
Endoplasmic reticulum aminopeptidase 2Homo sapiens (human)IC50 (µMol)7.94337.94337.94337.9433AID1664907
Leucyl-cystinyl aminopeptidaseHomo sapiens (human)Ki0.20350.00700.20350.8318AID329317; AID344305; AID344306; AID468341; AID601497
M17 leucyl aminopeptidasePlasmodium falciparum 3D7IC50 (µMol)1.53001.000027.8360138.0800AID1619
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (55)

Processvia Protein(s)Taxonomy
angiogenesisAminopeptidase NHomo sapiens (human)
cell differentiationAminopeptidase NHomo sapiens (human)
symbiont entry into host cellAminopeptidase NHomo sapiens (human)
proteolysisAminopeptidase NHomo sapiens (human)
peptide catabolic processAminopeptidase NHomo sapiens (human)
lipid metabolic processInterleukin-1 receptor antagonist proteinHomo sapiens (human)
immune responseInterleukin-1 receptor antagonist proteinHomo sapiens (human)
signal transductionInterleukin-1 receptor antagonist proteinHomo sapiens (human)
insulin secretionInterleukin-1 receptor antagonist proteinHomo sapiens (human)
negative regulation of heterotypic cell-cell adhesionInterleukin-1 receptor antagonist proteinHomo sapiens (human)
response to glucocorticoidInterleukin-1 receptor antagonist proteinHomo sapiens (human)
negative regulation of interleukin-1-mediated signaling pathwayInterleukin-1 receptor antagonist proteinHomo sapiens (human)
inflammatory response to antigenic stimulusInterleukin-1 receptor antagonist proteinHomo sapiens (human)
regulation of cell growthType-1 angiotensin II receptorHomo sapiens (human)
kidney developmentType-1 angiotensin II receptorHomo sapiens (human)
renin-angiotensin regulation of aldosterone productionType-1 angiotensin II receptorHomo sapiens (human)
maintenance of blood vessel diameter homeostasis by renin-angiotensinType-1 angiotensin II receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinType-1 angiotensin II receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayType-1 angiotensin II receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationType-1 angiotensin II receptorHomo sapiens (human)
Rho protein signal transductionType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationType-1 angiotensin II receptorHomo sapiens (human)
regulation of vasoconstrictionType-1 angiotensin II receptorHomo sapiens (human)
calcium-mediated signalingType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of phospholipase A2 activityType-1 angiotensin II receptorHomo sapiens (human)
low-density lipoprotein particle remodelingType-1 angiotensin II receptorHomo sapiens (human)
regulation of renal sodium excretionType-1 angiotensin II receptorHomo sapiens (human)
angiotensin-activated signaling pathwayType-1 angiotensin II receptorHomo sapiens (human)
regulation of cell population proliferationType-1 angiotensin II receptorHomo sapiens (human)
symbiont entry into host cellType-1 angiotensin II receptorHomo sapiens (human)
regulation of inflammatory responseType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of inflammatory responseType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of protein metabolic processType-1 angiotensin II receptorHomo sapiens (human)
cell chemotaxisType-1 angiotensin II receptorHomo sapiens (human)
phospholipase C-activating angiotensin-activated signaling pathwayType-1 angiotensin II receptorHomo sapiens (human)
blood vessel diameter maintenanceType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesisType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of CoA-transferase activityType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processType-1 angiotensin II receptorHomo sapiens (human)
inflammatory responseType-1 angiotensin II receptorHomo sapiens (human)
adaptive immune responseEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
antigen processing and presentation of peptide antigen via MHC class IEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
regulation of blood pressureEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
peptide catabolic processEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
proteolysisEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
angiogenesisEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
adaptive immune responseEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
antigen processing and presentation of peptide antigen via MHC class IEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
membrane protein ectodomain proteolysisEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
regulation of blood pressureEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
response to bacteriumEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
regulation of innate immune responseEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
fat cell differentiationEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
positive regulation of angiogenesisEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
peptide catabolic processEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
proteolysisEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
protein polyubiquitinationLeucyl-cystinyl aminopeptidaseHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independentLeucyl-cystinyl aminopeptidaseHomo sapiens (human)
cell-cell signalingLeucyl-cystinyl aminopeptidaseHomo sapiens (human)
female pregnancyLeucyl-cystinyl aminopeptidaseHomo sapiens (human)
protein catabolic processLeucyl-cystinyl aminopeptidaseHomo sapiens (human)
negative regulation of cold-induced thermogenesisLeucyl-cystinyl aminopeptidaseHomo sapiens (human)
peptide catabolic processLeucyl-cystinyl aminopeptidaseHomo sapiens (human)
regulation of blood pressureLeucyl-cystinyl aminopeptidaseHomo sapiens (human)
proteolysisLeucyl-cystinyl aminopeptidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (21)

Processvia Protein(s)Taxonomy
virus receptor activityAminopeptidase NHomo sapiens (human)
aminopeptidase activityAminopeptidase NHomo sapiens (human)
metallopeptidase activityAminopeptidase NHomo sapiens (human)
signaling receptor activityAminopeptidase NHomo sapiens (human)
metalloaminopeptidase activityAminopeptidase NHomo sapiens (human)
zinc ion bindingAminopeptidase NHomo sapiens (human)
peptide bindingAminopeptidase NHomo sapiens (human)
cytokine activityInterleukin-1 receptor antagonist proteinHomo sapiens (human)
interleukin-1, type I receptor bindingInterleukin-1 receptor antagonist proteinHomo sapiens (human)
interleukin-1, type II receptor bindingInterleukin-1 receptor antagonist proteinHomo sapiens (human)
interleukin-1 receptor antagonist activityInterleukin-1 receptor antagonist proteinHomo sapiens (human)
protein bindingInterleukin-1 receptor antagonist proteinHomo sapiens (human)
interleukin-1 type I receptor antagonist activityInterleukin-1 receptor antagonist proteinHomo sapiens (human)
interleukin-1 type II receptor antagonist activityInterleukin-1 receptor antagonist proteinHomo sapiens (human)
angiotensin type I receptor activityType-1 angiotensin II receptorHomo sapiens (human)
angiotensin type II receptor activityType-1 angiotensin II receptorHomo sapiens (human)
protein bindingType-1 angiotensin II receptorHomo sapiens (human)
bradykinin receptor bindingType-1 angiotensin II receptorHomo sapiens (human)
protein heterodimerization activityType-1 angiotensin II receptorHomo sapiens (human)
endopeptidase activityEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
aminopeptidase activityEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
protein bindingEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
metallopeptidase activityEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
zinc ion bindingEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
metalloaminopeptidase activityEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
peptide bindingEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
endopeptidase activityEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
aminopeptidase activityEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
interleukin-6 receptor bindingEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
interleukin-1, type II receptor bindingEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
protein bindingEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
metalloexopeptidase activityEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
zinc ion bindingEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
peptide bindingEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
metalloaminopeptidase activityEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
aminopeptidase activityLeucyl-cystinyl aminopeptidaseHomo sapiens (human)
protein bindingLeucyl-cystinyl aminopeptidaseHomo sapiens (human)
metallopeptidase activityLeucyl-cystinyl aminopeptidaseHomo sapiens (human)
metalloaminopeptidase activityLeucyl-cystinyl aminopeptidaseHomo sapiens (human)
zinc ion bindingLeucyl-cystinyl aminopeptidaseHomo sapiens (human)
peptide bindingLeucyl-cystinyl aminopeptidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
extracellular spaceAminopeptidase NHomo sapiens (human)
lysosomal membraneAminopeptidase NHomo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentAminopeptidase NHomo sapiens (human)
plasma membraneAminopeptidase NHomo sapiens (human)
external side of plasma membraneAminopeptidase NHomo sapiens (human)
secretory granule membraneAminopeptidase NHomo sapiens (human)
extracellular exosomeAminopeptidase NHomo sapiens (human)
cytoplasmAminopeptidase NHomo sapiens (human)
plasma membraneAminopeptidase NHomo sapiens (human)
extracellular spaceAminopeptidase NHomo sapiens (human)
extracellular spaceInterleukin-1 receptor antagonist proteinHomo sapiens (human)
nucleoplasmInterleukin-1 receptor antagonist proteinHomo sapiens (human)
centrosomeInterleukin-1 receptor antagonist proteinHomo sapiens (human)
cytosolInterleukin-1 receptor antagonist proteinHomo sapiens (human)
plasma membraneInterleukin-1 receptor antagonist proteinHomo sapiens (human)
extracellular exosomeInterleukin-1 receptor antagonist proteinHomo sapiens (human)
extracellular spaceInterleukin-1 receptor antagonist proteinHomo sapiens (human)
plasma membraneType-1 angiotensin II receptorHomo sapiens (human)
membraneType-1 angiotensin II receptorHomo sapiens (human)
plasma membraneType-1 angiotensin II receptorHomo sapiens (human)
endoplasmic reticulum lumenEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
endoplasmic reticulum membraneEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
extracellular spaceEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
membraneEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
cytoplasmEndoplasmic reticulum aminopeptidase 2Homo sapiens (human)
extracellular regionEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
extracellular spaceEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
endoplasmic reticulumEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
endoplasmic reticulum lumenEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
endoplasmic reticulum membraneEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
cytosolEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
membraneEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
extracellular exosomeEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
extracellular spaceEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
cytoplasmEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
membraneEndoplasmic reticulum aminopeptidase 1Homo sapiens (human)
lysosomal membraneLeucyl-cystinyl aminopeptidaseHomo sapiens (human)
cytosolLeucyl-cystinyl aminopeptidaseHomo sapiens (human)
plasma membraneLeucyl-cystinyl aminopeptidaseHomo sapiens (human)
membraneLeucyl-cystinyl aminopeptidaseHomo sapiens (human)
cytoplasmic vesicle membraneLeucyl-cystinyl aminopeptidaseHomo sapiens (human)
early endosome lumenLeucyl-cystinyl aminopeptidaseHomo sapiens (human)
perinuclear region of cytoplasmLeucyl-cystinyl aminopeptidaseHomo sapiens (human)
plasma membraneLeucyl-cystinyl aminopeptidaseHomo sapiens (human)
extracellular spaceLeucyl-cystinyl aminopeptidaseHomo sapiens (human)
cytoplasmLeucyl-cystinyl aminopeptidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (39)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1346995Human AT1 receptor (Angiotensin receptors)2002The Journal of biological chemistry, Jun-28, Volume: 277, Issue:26
Angiotensin IV is a potent agonist for constitutive active human AT1 receptors. Distinct roles of the N-and C-terminal residues of angiotensin II during AT1 receptor activation.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID468341Inhibition of catalytic activity of human IRAP transfected in HEK293 cells assessed as formation of p-nitroaniline2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
The replacement of His(4) in angiotensin IV by conformationally constrained residues provides highly potent and selective analogues.
AID344305Displacement of [125I]Angiotensin 4 from human recombinant IRAP expressed in CHOK1 cells2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Ligands to the (IRAP)/AT4 receptor encompassing a 4-hydroxydiphenylmethane scaffold replacing Tyr2.
AID329317Inhibition of human recombinant IRAP expressed in HEK293 cells2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Beta-homo-amino acid scan of angiotensin IV.
AID601499Displacement of [3H]AL-11 from IRAP of CHO-K1 cell membrane preincubated for 40 mins in presence of 30 mM EDTA and 600 uM 1,10-Phenantrone after 30 mins by scintillation counting2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Potent macrocyclic inhibitors of insulin-regulated aminopeptidase (IRAP) by olefin ring-closing metathesis.
AID1664906Inhibition of human IRAP soluble domain expressed in HEK293S GnTI(-) cells using Leu-AMC as substrate incubated for 2 hrs by fluorescence based assay2020ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7
Structural Basis of Inhibition of Insulin-Regulated Aminopeptidase by a Macrocyclic Peptidic Inhibitor.
AID1146282Relative binding affinity of the compound assessed as ratio of [Asp1,Ile5]angiotensin II ED50 to compound ED50 for angiotensin 2 receptor in rabbit aortic strips1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Biologically active derivatives of angiotensin for labeling cellular receptors.
AID329321Displacement of [3H]valsartan from human AT1 receptor expressed in CHO cells2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Beta-homo-amino acid scan of angiotensin IV.
AID468340Inhibition of catalytic activity of human aminopeptidase N transfected in HEK293 cells assessed as formation of p-nitroaniline2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
The replacement of His(4) in angiotensin IV by conformationally constrained residues provides highly potent and selective analogues.
AID344307Inhibition of human recombinant APN expressed in HEK293 cells2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Ligands to the (IRAP)/AT4 receptor encompassing a 4-hydroxydiphenylmethane scaffold replacing Tyr2.
AID601498Inhibition of catalytic activity of recombinant human AP-N transfected in human HEK-293 cells assessed as cleavage of substrate L-leucine-p-nitroanilide to L-leucine and p-nitroaniline measured every 5 mins for 10 to 50 mins by spectrophotometric analysis2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Potent macrocyclic inhibitors of insulin-regulated aminopeptidase (IRAP) by olefin ring-closing metathesis.
AID344306Inhibition of human recombinant IRAP expressed in HEK293 cells2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Ligands to the (IRAP)/AT4 receptor encompassing a 4-hydroxydiphenylmethane scaffold replacing Tyr2.
AID329319Displacement of [125]Ang4 from endogenous IRAP in CHOK1 cell membrane in presence of EDTA and 1,10-phenanthroline2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Beta-homo-amino acid scan of angiotensin IV.
AID601497Inhibition of catalytic activity of recombinant human IRAP transfected in human HEK-293 cells assessed as cleavage of substrate L-leucine-p-nitroanilide to L-leucine and p-nitroaniline measured every 5 mins for 10 to 50 mins by spectrophotometric analysis2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Potent macrocyclic inhibitors of insulin-regulated aminopeptidase (IRAP) by olefin ring-closing metathesis.
AID468344Displacement of [3H]valsartan from human recombinant AT1 receptor expressed in CHO cells after 40 mins by liquid scintillation counting2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
The replacement of His(4) in angiotensin IV by conformationally constrained residues provides highly potent and selective analogues.
AID1664907Inhibition of ERAP2 (unknown origin) using Arg-AMC as substrate by fluorescence based assay2020ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7
Structural Basis of Inhibition of Insulin-Regulated Aminopeptidase by a Macrocyclic Peptidic Inhibitor.
AID601500Displacement of [3H]AL-11 from IRAP of CHO-K1 cell membrane after 30 mins by scintillation counting in presence of 30 mM EDTA and 600 uM 1,10-Phenantrone2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Potent macrocyclic inhibitors of insulin-regulated aminopeptidase (IRAP) by olefin ring-closing metathesis.
AID329318Inhibition of human recombinant APN expressed in HEK293 cells2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Beta-homo-amino acid scan of angiotensin IV.
AID1664908Inhibition of ERAP1 (unknown origin) using Leu-AMC as substrate by fluorescence based assay2020ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7
Structural Basis of Inhibition of Insulin-Regulated Aminopeptidase by a Macrocyclic Peptidic Inhibitor.
AID329320Displacement of [125]Ang4 from endogenous IRAP in CHOK1 cell membrane2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Beta-homo-amino acid scan of angiotensin IV.
AID468342Selectivity ratio of Ki for human aminopeptidase N to Ki for human IRAP2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
The replacement of His(4) in angiotensin IV by conformationally constrained residues provides highly potent and selective analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (299)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (1.34)18.7374
1990's90 (30.10)18.2507
2000's125 (41.81)29.6817
2010's68 (22.74)24.3611
2020's12 (4.01)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.34 (24.57)
Research Supply Index5.76 (2.92)
Research Growth Index6.10 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (1.61%)5.53%
Reviews33 (10.61%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other273 (87.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]